National
Desk
| May 20, 2003, Tuesday
Leading
Drugs for Psychosis Come Under New Scrutiny
By ERICA GOODE (NYT) 3459 words
Late Edition - Final , Section A ,
Page 1 , Column 3
ABSTRACT
- Researchers suggest that new generation of
antipsychotic drugs, called atypicals, may
not be as effective as first thought when
they were introduced 14 years ago, and may
have dangerous side effects; studies find
their superiority is at best modest,
specific to certain symptoms and variable
from drug to drug; there is increasing
suspicion that they may cause serious side
effects, notably diabetes, in some cases
leading to death; issue of risks has become
more pressing as drugs are prescribed for
children and for adults with milder
conditions; experts say drugs' benefits must
be balanced by side effects and cost; more
than 15 million prescriptions were written
last year for Zyprexa and Risperdal, two
leading drugs; when first introduced, they
appeared so successful in treating psychotic
illness that doctors began prescribing them
for other conditions, including nonpsychotic
depression, conduct disorder and severe
aggression in children; detailed look at
drugs' growth since 1990; photo; graphs;
charts (L) They were billed as near wonder
drugs, much safer and more effective in
treating schizophrenia than anything that
had come before.
For many years, it seemed that the
excitement was fully warranted.
How multi-packs work: A
multi-pack is an archive package that saves
you money by allowing you to pre-purchase a
set number of articles in bulk at a reduced
price. You can then debit from your
multi-pack and quickly access articles from
the archive at your convenience over the
lifetime of the multi-pack.
Once you purchase an
article, you may view it as often as you
like over the next 90 days. Archive articles
do not include photos, charts or graphics
Click here to purchase article if you
already own an archive article pack.
|